[Skip to Content]
[Skip to Content Landing]
Views 2,371
Citations 0
Invited Commentary
January 2019

Hereditary Breast and Ovarian Cancer Testing in the Genomic Era

Author Affiliations
  • 1Cancer Sciences Unit, University of Southampton, University Hospital Southampton, Southampton, United Kingdom
  • 2Wessex Clinical Genetics Service, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
JAMA Oncol. 2019;5(1):58-59. doi:10.1001/jamaoncol.2018.3034

Advances in next-generation sequencing and the decreasing cost of technology have widened access to cancer genomic testing. This development has enabled a shift from iterative, single-gene testing based on the presenting cancer phenotype to more broad-based genomic tests, including targeted cancer susceptibility gene panels and exome sequencing with directed in silico analysis. The potential benefits of this approach include an increase in diagnostic yield and identification of actionable risk. Nevertheless, it remains difficult to determine the cancer risk associated with many breast or ovarian cancer susceptibility genes. This is especially true for those genes that confer a moderate risk with confidence intervals that may be wide, and factors other than a single genotype may influence risk estimates. Developing optimal clinical management guidelines is a challenge in this context. Furthermore, these challenges have resulted in some variation in the genes that are included on hereditary breast or ovarian cancer susceptibility gene panels.

×